Guggenheim Capital LLC Sells 9,280 Shares of Intercept Pharmaceuticals Inc (ICPT)

Guggenheim Capital LLC trimmed its stake in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 20.1% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 36,911 shares of the biopharmaceutical company’s stock after selling 9,280 shares during the quarter. Guggenheim Capital LLC’s holdings in Intercept Pharmaceuticals were worth $2,157,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Legal & General Group Plc lifted its stake in Intercept Pharmaceuticals by 48.2% in the third quarter. Legal & General Group Plc now owns 8,856 shares of the biopharmaceutical company’s stock valued at $514,000 after buying an additional 2,882 shares during the last quarter. Peregrine Capital Management LLC bought a new stake in Intercept Pharmaceuticals in the fourth quarter valued at $7,055,000. Hudson Bay Capital Management LP bought a new stake in Intercept Pharmaceuticals in the fourth quarter valued at $1,753,000. Amalgamated Bank bought a new stake in Intercept Pharmaceuticals in the fourth quarter valued at $209,000. Finally, State of Wisconsin Investment Board lifted its stake in Intercept Pharmaceuticals by 221.0% in the fourth quarter. State of Wisconsin Investment Board now owns 11,689 shares of the biopharmaceutical company’s stock valued at $683,000 after buying an additional 8,047 shares during the last quarter. Institutional investors own 74.27% of the company’s stock.

How to Become a New Pot Stock Millionaire

A number of research firms have issued reports on ICPT. Oppenheimer reiterated a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Monday, January 29th. Wedbush reiterated an “outperform” rating and issued a $253.00 target price (down from $256.00) on shares of Intercept Pharmaceuticals in a research note on Friday, March 9th. ValuEngine upgraded Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, April 4th. Citigroup set a $74.00 target price on Intercept Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, December 21st. Finally, BidaskClub upgraded Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 25th. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $128.75.

In other news, CEO Mark Pruzanski bought 7,812 shares of the stock in a transaction that occurred on Monday, April 9th. The shares were purchased at an average cost of $64.00 per share, with a total value of $499,968.00. Following the completion of the acquisition, the chief executive officer now directly owns 11,642 shares in the company, valued at $745,088. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Keith Michael Gottesdiener bought 1,171 shares of the stock in a transaction that occurred on Monday, April 9th. The shares were purchased at an average cost of $64.00 per share, for a total transaction of $74,944.00. Following the completion of the acquisition, the director now owns 5,001 shares of the company’s stock, valued at $320,064. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 399,608 shares of company stock worth $25,574,912. 9.20% of the stock is owned by corporate insiders.

Shares of NASDAQ ICPT opened at $73.07 on Monday. Intercept Pharmaceuticals Inc has a fifty-two week low of $51.05 and a fifty-two week high of $135.59. The company has a current ratio of 4.31, a quick ratio of 4.31 and a debt-to-equity ratio of 21.71. The stock has a market cap of $2,083.39, a P/E ratio of -5.08 and a beta of -1.82.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.04). The firm had revenue of $37.69 million for the quarter, compared to analyst estimates of $39.01 million. Intercept Pharmaceuticals had a negative return on equity of 267.95% and a negative net margin of 275.18%. Intercept Pharmaceuticals’s revenue was up 173.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($4.84) earnings per share. analysts predict that Intercept Pharmaceuticals Inc will post -12.6 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/16/guggenheim-capital-llc-sells-9280-shares-of-intercept-pharmaceuticals-inc-icpt.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals Inc (NASDAQ:ICPT).

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply